Crewe Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Crewe Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-314	Closed	-$1.09K	–	977
2023 Q1	$1.09K	Hold	314	–	–	﹤0.01%	752
2022 Q4	$769	Hold	314	–	–	﹤0.01%	944
2022 Q3	$1K	Hold	314	–	–	﹤0.01%	1173
2022 Q2	$1K	Buy	+314	New	+$996	﹤0.01%	1091

Other funds holding OLMA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Crewe Advisors's OLMA Position: Q2 2023 in Review

Crewe Advisors sold out of Olema Pharmaceuticals (OLMA) in Q2 2023, closing a stake of 314 shares — an estimated $1.09K sold.

Crewe Advisors first reported a position in OLMA in Q2 2022 and held it in 4 quarters. The position peaked at $1.09K in Q1 2023. 87 funds tracked by Wall St. Rank hold OLMA as of Q2 2023.

Crewe Advisors reported no remaining Olema Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 314 Olema Pharmaceuticals shares in Q2 2023, an estimated $1.09K.
Crewe Advisors first reported a position in Olema Pharmaceuticals in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Olema Pharmaceuticals position peaked at $1.09K in Q1 2023.
87 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.